Mirjam Kok
Overview
Explore the profile of Mirjam Kok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
115
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roossink F, Wieringa H, Noordhuis M, ten Hoor K, Kok M, Slagter-Menkema L, et al.
Int J Cancer
. 2012 Feb;
131(9):2056-66.
PMID: 22323184
Treatment of advanced-stage cervical cancers with (chemo)radiation causes cytotoxicity through induction of high levels of DNA damage. Tumour cells respond to DNA damage by activation of the 'DNA damage response'...
2.
Noordhuis M, Fehrmann R, Wisman G, Nijhuis E, van Zanden J, Moerland P, et al.
Clin Cancer Res
. 2011 Mar;
17(6):1317-30.
PMID: 21385933
Purpose: Presence of pelvic lymph node metastases is the main prognostic factor in early-stage cervical cancer patients, primarily treated with surgery. Aim of this study was to identify cellular tumor...
3.
Eijsink J, Noordhuis M, ten Hoor K, Kok M, Hollema H, de Bock G, et al.
Hum Pathol
. 2010 Nov;
41(12):1735-41.
PMID: 21078436
The objective of this study is to correlate the expression of epidermal growth factor receptor (EGFR) components with clinical behavior of early-stage cervical cancer. Tissue samples of 336 consecutive Federation...
4.
Bijman M, van Berkel M, Kok M, Janmaat M, Boven E
Anticancer Drugs
. 2009 Apr;
20(6):450-60.
PMID: 19369859
Human epidermal growth factor (HER) family-targeted therapy combined with standard cytotoxic agents might improve the treatment of ovarian cancer. Human ovarian cancer cell lines OVCAR-3, IGROV-1, and SKOV-3 with differential...